Targeted therapies are substantially changing the management of lung cancers. These
treatments include drugs that target driver mutations, those that target presumed important …

The fibroblast growth factor receptor (FGFR) cascade plays crucial roles in tumor cell
proliferation, angiogenesis, migration and survival. Accumulating evidence suggests that in …

Purpose: Molecular profiling may have prognostic and predictive value, and is increasingly
used in the clinical setting. There are more than a dozen fibroblast growth factor receptor …

Objectives Gut microbiome plays a dominant role in modulating therapeutic efficacy of
immune checkpoint inhibitors (ICIs) targeting the programmed cell death receptor/ligand-1 …

Lung cancer is a leading cause of cancer-related mortality worldwide, and is classically
divided into two major histological subtypes: non-small-cell lung cancer (NSCLC) and small …

Epithelial–mesenchymal transition (EMT) is an important process for cancer metastasis,
drug resistance, and cancer stem cells. Activation of fibroblast growth factor receptor 1 …

Historically, patients with advanced stage non‐small cell lung cancer (NSCLC) were treated
with chemotherapy alone, but a therapeutic plateau has been reached. Advances in the …

Large-scale genomic characterization of squamous cell lung cancers (SQCLC) has revealed
several putative oncogenic drivers. There are, however, little data to suggest that these …

The landscape of advanced non-small lung cancer (NSCLC) therapies has rapidly been
evolving beyond chemotherapy over the last few years. The discovery of oncogenic driver …

There have been significant advances in the understanding of the biology and treatment of
non–small-cell lung cancer (NSCLC) during the past few years. A number of molecularly …